$ABBV

AbbVie said its neuroscience franchise grew in 1H 2026, with sales of $6.1B, up 21.8% year over year on an operational basis. Vraylar led at $1.98B (+18.6%), with Ubrelvy $731M (+26.4%), Qulipta $646M (+39.2%), Botox $2.05B (+13.2%), and Vyalev $457M. AbbVie raised 2026 neuroscience guidance to about $12.7B (+$100M) and overall revenue to about $67.6B (+$300M). It expects an FDA decision on tavapadon for PD in 3Q 2026.

The article compares Johnson & Johnson (JNJ) and AbbVie (ABBV) on dividends and recent results. JNJ reported Q2 worldwide sales of $25.3B and highlights a 64-year dividend increase streak with a 2.02% yield. ABBV reported nearly $17B revenue, a 2.78% yield, Skyrizi up 24% to $5.5B, Humira down 36.1% to $706M, and a $10.9B Apogee Therapeutics acquisition that reduces 2026 EPS by $0.14.

AbbVie (ABBV) reported revenue growth of 10.4% and a 34% operating margin over the past year, with immunology drug sales rising 24% for SKYRIZI and RINVOQ. Despite strong fundamentals and a 10.2% sales growth quarter, ABBV’s 12-month stock return was about 30%, lagging peers like Merck (+67%) and J&J (+54%). The article says the market may be pricing future competitive risks, citing questions on SKYRIZI durability and crowded development for new indications.

A medtech notified-bodies trade group, Team-NB, urged EU authorities to grant notified bodies access to Eudamed to support proposed risk-based surveillance under pending medical device reforms. Team-NB said current access is limited to certain modules and asked that EMA and notified bodies access all referenced systems. Separately, EDQM reactivated a botulinum toxin working party to phase out LD50 mouse testing.

Genmab and AbbVie said the Phase 3 EPCORE DLBCL-1 trial of epcoritamab failed its U.S. overall survival primary endpoint, though the drug keeps accelerated FDA approval. Genmab reported H1 2026 revenue of $2.051B and raised 2026 guidance to $4.325–$4.525B. AbbVie reported Q2 2026 net revenues of $16.99B and EPS $3.65.

AbbVie (ABBV) reported Q1 2026 net revenues of $15.002B (+12.4% reported) and GAAP diluted EPS of $0.39, with adjusted diluted EPS of $2.65. AbbVie raised full-year 2026 adjusted EPS guidance to $14.08–$14.28. AbbVie’s Allergan Aesthetics said the EU approved Boey (trenibotulinumtoxinE) in all EEA countries. Canaccord raised its ABBV price target to $282.

Wolfe Research upgraded Biogen and AbbVie to Outperform, setting $300 price targets for each. For Biogen, it cited late-stage pipeline catalysts for litifilimab and felzartamab and said the Apellis acquisition strengthens near-term revenue. For AbbVie, it cited valuation, limited near-term loss-of-exclusivity risk, and multiple upcoming clinical catalysts.

Biopharma M&A in 2026 is estimated at $130B across 42 deals, nearly matching 2025’s $133B, according to IQVIA. Average deal size rose to $3.1B. The article cites patent expirations as a driver and highlights deals including GSK-Nuvalent ($10.6B), Merck-Terns ($6.7B), AbbVie-Apogee ($10.9B), Curium-Lantheus (up to $8B), Eli Lilly-Centessa ($7.8B), and Sun Pharma-Organon ($11.75B).

DelveInsight’s 2026 report says 45+ pharma companies are developing 52+ postoperative pain management drugs across clinical stages. It highlights late and mid-stage programs including Ensysce’s PF614 (Phase III), Xgene’s XG005 (II/III), and Jiangsu Hengrui’s HRS-2129 (II/III). It also cites AbbVie’s April 2026 deal with Haisco (USD 30M upfront, up to USD 705M milestones) and recent trial/enrollment updates.

Alnylam reported $1.01B in Q2 Amvuttra sales, below consensus, and trimmed 2026 revenue guidance for its transthyretin franchise by $200M to $4.2B-$4.5B, citing normalized second-line demand. The article also notes AbbVie’s Imbruvica Q2 $532M vs ~$533M, Merck’s vaccines slightly below expectations, and Roche’s Vabysmo $1.27B vs consensus.